RxDoctor Payments Data

Jose Cabrales, MD

Nephrology · Bear, DENPI 1598251068

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in DE, where the typical reported total is $2,465.

$1,272in general payments, 2019–2025

Across 41 payments — averaging $31.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$242
  • AstraZeneca$229
  • Amgen$162
  • Akebia Therapeutics Inc$152
  • Ardelyx, Inc.$138
  • Novartis$94
  • plus $256 from 8 others

What the payments were for

  • Food & beverage$1,272100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,272 in reported general payments places this provider in the 30th percentile of 49 nephrology providers in Delaware.

See all nephrology providers in Delaware

Medicare billing

Part B allowed, 2024
$217,458
Medicare patients
413
Services billed
2,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$20,690
FarxigaDapagliflozin Propanediol20$19,609
Clonidine12$2,518
Calcitriol104$2,290
Amlodipine Besylate115$957
Losartan Potassium82$847
Lisinopril70$845
Bumetanide23$831
Metoprolol Succinate40$568
Furosemide80$499
Hydralazine Hcl33$428
Carvedilol44$384
Clonidine Hcl12$323
Tamsulosin Hcl16$296
Potassium Chloride15$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$20,69013 claims
AstraZenecaFarxiga$229$19,60920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 49 nephrology providers in Delaware.

Other nephrology in Bear

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →